Arkadios Wealth Advisors Buys Shares of 7,371 The Clorox Company $CLX

Arkadios Wealth Advisors purchased a new position in shares of The Clorox Company (NYSE:CLX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 7,371 shares of the company’s stock, valued at approximately $909,000.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. raised its stake in Clorox by 138.3% during the second quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock worth $389,648,000 after buying an additional 1,883,465 shares during the last quarter. Norges Bank acquired a new stake in Clorox during the 2nd quarter worth about $190,429,000. Arrowstreet Capital Limited Partnership raised its position in shares of Clorox by 218.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after acquiring an additional 856,873 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Clorox in the 2nd quarter valued at about $71,856,000. Finally, Nuance Investments LLC boosted its position in shares of Clorox by 182.5% during the 2nd quarter. Nuance Investments LLC now owns 848,106 shares of the company’s stock valued at $101,832,000 after purchasing an additional 547,839 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

Clorox Stock Performance

NYSE CLX opened at $113.46 on Friday. The company has a market cap of $13.84 billion, a P/E ratio of 17.81, a PEG ratio of 0.57 and a beta of 0.58. The company has a fifty day simple moving average of $103.80 and a 200 day simple moving average of $114.78. The company has a current ratio of 0.76, a quick ratio of 0.50 and a debt-to-equity ratio of 18.01. The Clorox Company has a 12-month low of $96.66 and a 12-month high of $164.22.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The business’s quarterly revenue was down 18.9% compared to the same quarter last year. During the same period last year, the firm earned $1.86 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Sell-side analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 dividend on an annualized basis and a yield of 4.4%. Clorox’s payout ratio is 77.86%.

Trending Headlines about Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox agreed to acquire GOJO Industries, the maker of Purell, for $2.25 billion in cash — a strategic push deeper into skin health and hygiene that management says is growth‑accretive and advances its IGNITE plan. The deal expands Clorox’s consumer and professional hygiene footprint and is the primary catalyst for today’s stock strength. Clorox Announces Acquisition of GOJO
• Positive Sentiment: Management updated FY‑2026 EPS guidance to $5.95–$6.30, slightly above consensus, and reiterated revenue targets — a sign the company expects the combined portfolio and cost initiatives to help stabilize growth. This guidance helped reassure investors even as organic revenue pressures persist. (Company guidance release)
• Neutral Sentiment: Deutsche Bank raised its price target on CLX to $114 (keeps a Hold rating), a small incremental positive that signals modest upside in analysts’ view but not a strong buy signal. Deutsche Bank Raises Price Target
• Neutral Sentiment: Broad media and analyst coverage (WSJ, CNBC, MarketWatch) has amplified the deal’s reach and provided investors with deal details and management commentary — increasing attention but not resolving long‑term execution questions. WSJ: Clorox to Buy Purell-Maker
• Negative Sentiment: Some sell‑side skepticism remains: Barclays kept an Underweight (sell) stance despite a small target tweak, and commentary from critics highlights valuation and fundamental concerns that could limit upside until integration is proven. Barclays Remains a Sell
• Negative Sentiment: The deal is being financed with debt, increasing leverage and short‑term balance‑sheet risk; investors will watch integration execution and cost synergy realization closely — these risks are why some analysts remain cautious. WSJ: Deal Financed with Debt
• Negative Sentiment: Critical commentary (e.g., Seeking Alpha) questions whether the acquisition meaningfully fixes Clorox’s underlying growth challenges and suggests the company still needs stronger organic execution — a narrative that could cap the stock if results don’t improve. Seeking Alpha: Adding Sanitizers, But In Need Of Getting Its Hands Dirty

Insider Buying and Selling

In related news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Friday, November 21st. The stock was purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the purchase, the director directly owned 13,000 shares in the company, valued at $1,353,690. This trade represents a 44.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Analyst Upgrades and Downgrades

CLX has been the subject of a number of research analyst reports. Morgan Stanley lowered their target price on Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Rothschild & Co Redburn lowered their price objective on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Barclays reiterated an “underweight” rating and set a $109.00 target price on shares of Clorox in a research report on Friday, January 16th. Jefferies Financial Group restated a “buy” rating and issued a $152.00 price target on shares of Clorox in a report on Tuesday, November 4th. Finally, Wall Street Zen downgraded shares of Clorox from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating, thirteen have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $122.19.

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.